Hylevo-M Tablet contains Levocetirizine 5mg and Montelukast 10mg, combining an antihistamine and a leukotriene receptor antagonist to provide effective relief from allergic conditions. Levocetirizine, a third-generation non-sedating antihistamine, selectively inhibits peripheral H1 receptors, thereby reducing symptoms such as sneezing, rhinorrhea, nasal congestion, and pruritus associated with allergic rhinitis and chronic urticaria. Montelukast, a leukotriene receptor antagonist, blocks the action of cysteinyl leukotrienes, which are inflammatory mediators involved in bronchoconstriction, mucus production, and airway edema, making it beneficial in the management of asthma and allergic rhinitis. The combination of these two agents offers a synergistic effect, improving symptom control in patients with seasonal or perennial allergic rhinitis and asthma. Hylevo-M is indicated for the relief of symptoms associated with allergic rhinitis, chronic idiopathic urticaria, and as an adjunct in asthma management to reduce bronchospasm and inflammation. It is generally well-tolerated, with a low incidence of sedation or adverse effects. Dosage and administration should follow physician guidance, considering patient-specific factors such as age, severity of symptoms, and comorbid conditions. Regular monitoring is advised to assess therapeutic response and detect any potential side effects.